Short-term effectiveness of bupropion for assisting smoking cessation in general practice

Nicholas A Zwar, Alia Nasser, Elizabeth J Comino and Robyn L Richmond
Med J Aust 2002; 177 (5): . || doi: 10.5694/j.1326-5377.2002.tb04772.x
Published online: 2 September 2002

To the Editor: As noted in the letter by Chapman and Jamrozik,1 there was substantial prescribing of bupropion sustained release (Zyban SR; GlaxoSmithKline) following its Pharmaceutical Benefits Scheme (PBS) listing from 1 February 2001. The drug has been the subject of extensive publicity following reports of adverse drug reactions and deaths of patients while taking bupropion. Although bupropion has been shown to be effective in two key clinical trials,2,3 there are no studies of effectiveness when prescribed in the context of Australian general practice.

  • Nicholas A Zwar
  • Alia Nasser
  • Elizabeth J Comino
  • Robyn L Richmond



The contribution of the general practice registrars and the support provided by the Primary Health Care Research Network to this project is gratefully acknowledged.

Competing interests:

NAZ and RLR have received funding from GlaxoSmithKline to conduct education programs in smoking cessation for health professionals.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.